Jubilant Pharmova Q4 Profit Slips 21% to Rs 119 Cr Despite Revenue Growth

Written By :  sheeba farhat
Published On 2026-05-23 11:43 GMT   |   Update On 2026-05-23 11:43 GMT

New Delhi: Jubilant Pharmova reported a 21 per cent decline in consolidated net profit to Rs 119.3 crore in the March quarter impacted by exceptional items outgo.

The company had posted a consolidated net profit of Rs 151.3 crore in the corresponding period of the previous fiscal year, Jubilant Pharmova Ltd said in a regulatory filing.

Consolidated total revenue from operations during the quarter stood at Rs 2,290 crore as compared to Rs 1,928.8 crore in the year-ago period, it added.

Total expenses during the quarter under review were higher at Rs 2,124 crore from Rs 1,731.3 crore in the corresponding period a year ago, the company said.

The company incurred exceptional items outgo of Rs 13.7 crore in the quarter.

The board has recommended a final dividend of Rs 5 per equity share of face value of Re 1 each for the financial year ended March 31, 2026, it said.

For FY26, consolidated profit was down at Rs 397.5 crore from Rs 836.3 crore in FY25. Consolidated total revenue from operations in FY26 stood at Rs 8,279.6 crore as compared to Rs 7,234.5 crore in FY25, the company said.

They said the company anticipates EBITDA margins to strengthen from H2 FY27 onwards post- stabilisation of production in Montreal, effectively offsetting higher depreciation costs and driving net profit growth.

"Revenue growth is particularly driven by incremental revenue generation from the new and third line in CDMO (contract development and manufacturing organisation) sterile injectable business," Jubilant Pharmova Chairman Shyam S Bhartia and Co-Chairman & Non-Executive Director Hari S Bhartia said in a joint statement.

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News